

SETTING THE SCENE:



CATHERINE ALIX-PANABIÈRES

Professor of Oncology (PU-PH), Faculty of
Medicine of Montpellier, France



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



VISION EUROPE 2030

DISRUPTIVE TECHNOLOGIES, DEMOCRATIZED TRIALS & NEXT-GEN TREATMENT PARADIGMS



September 2-3, 2025 | Club University Foundation




Co-funded by
the European Union

Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.



Prof. Catherine Alix-Panabières

University Medical Center of Montpellier



Democratizing Trials: Blueprint for inclusive innovation (*Liquid Biopsy*)



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE




Why This Session Matters ?

- Clinical trials = engine of innovation → but not inclusive enough
- **Result:** validated in 'ideal' patients → not scalable to real-world care.

The data obtained better reflect real-world clinical practice, and the recommendations will be more relevant for all patients with cancer, not just for an 'ideal' minority.



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



In This Session...

Rethink clinical research models in Europe.

- Make them inclusive, equitable, real-world aligned.
- AI-powered recruitment, decentralized trials, cross-border collaboration.
- Goal: faster and fairer innovation.



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



Liquid Biopsy as a Game-Changer

Non-invasive, repeatable, scalable → broader participation.


- Detects CTCs, ctDNA, Evs and more

- Unique potential:

Early detection

Minimal residual disease monitoring

Real-time treatment adaptation



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



From Innovation to Implementation

- Challenge: Many pilot LB studies, but fragmented integration in Europe.
- What's missing:
 - Inclusive trial design
 - Real-world evidence generation
 - Health system readiness (reimbursement, logistics, training)
- Europe risks lagging without coordinated action.



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



Vision for 2030

- Democratize trial access: hybrid models, community sites, remote sampling.
- Use real-world data to validate clinical utility.
- Ensure ctDNA, CTCs, EVs are accessible & equitable.
- Make precision oncology the standard of care in Europe.

➔ **Ensuring that innovations reach all patients.**



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



Call to Action

”If innovation is not inclusive, it is not precision medicine.”

- Let’s design trials & health systems where every patient benefits from *LB*.
- This session: moving from innovation → implementation → equity.



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE




Europe 2026–2030: Next Steps

Key EU Issues:

- Harmonize LB validation & trial endpoints.
- Regulatory alignment (EMA/FDA).
- Build EU-wide decentralized trial networks.
- Integrate *LB* into cancer registries.
- Equity: expand beyond top centers → community sites.



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



Europe 2026–2030: Next Steps

Concrete EU Actions:

EU Liquid Biopsy Platform (biobank + trial hub)

Common reimbursement frameworks

Training programs for clinicians/labs

Embed equity criteria in Horizon Europe & Cancer Mission calls

Public–private partnerships with biotech/AI

👉 The next 4 years will decide whether Europe leads or lags in LB democratization.



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE





A CALL TO ACTION

Join the movement!